NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Evaluating the Safety and Immune Response to Five Different Combinations of HIV Vaccines in Healthy, HIV-Uninfected Adults

Phase 1

Withdrawn

Conditions: HIV Infections

Interventions: Biological: DNA-HIV-PT123
Biological: NYVAC-HIV-PT1
Biological: NYVAC-HIV-PT4
Biological: AIDSVAX B/E®
Biological: Placebo vaccine

First Posted Date: 2013-10-17

Last Posted Date: 2021-10-15

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Registration Number: NCT01964937

Evaluation of Oral Activated Charcoal on Antimalarial Drug's Ability to Kill Parasites in Malian Children With Malaria

Phase 2

Completed

Conditions: Malaria
Severe Malaria

Interventions: Drug: Actidose Aqua
Drug: Artesunate
Drug: Amodiaquine

First Posted Date: 2013-10-07

Last Posted Date: 2018-02-06

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 70

Registration Number: NCT01955382

Locations: 🇲🇱
Universite des Sciencies, Techniques et Technologies de Bamako, Bamako, Mali

Trichuris Suis Ova Treatment in Left-sided Ulcerative Colitis

Phase 2

Terminated

Conditions: Colitis, Ulcerative

Interventions: Biological: Placebo
Biological: Trichuris suis ova (TSO)

First Posted Date: 2013-10-01

Last Posted Date: 2017-03-17

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 16

Registration Number: NCT01953354

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸
University of Miami Miller School of Medicine, Miami, Florida, United States
🇺🇸
University of Maryland, Baltimore, Maryland, United States

and more 14 locations

VRC 601: A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC HIVMAB060-00-AB (VRC01), With Broad HIV-1 Neutralizing Activity, Administered Intravenously or Subcutaneously to HIV-Infected...

Phase 1

Completed

Conditions: Viral Load
HIV Antibodies
Neutralizing Antibody
HIV-1 Infection
Monoclonal Antibody

Interventions: Biological: VRC-HIVMAB060-00-AB

First Posted Date: 2013-09-25

Last Posted Date: 2019-12-17

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 27

Registration Number: NCT01950325

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Safety and Effectiveness of Low-Dose Methotrexate for Reducing Inflammation in HIV-Infected Adults on ARV Medications

Phase 2

Completed

Conditions: HIV Infections

Interventions: Drug: LDMTX
Drug: Placebo
Dietary Supplement: Folic acid

First Posted Date: 2013-09-24

Last Posted Date: 2021-11-01

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 176

Registration Number: NCT01949116

Locations: 🇺🇸
Case Clinical Research Site, Cleveland, Ohio, United States
🇺🇸
University of Southern California CRS, Los Angeles, California, United States
🇺🇸
UCLA CARE Center CRS, Los Angeles, California, United States

and more 19 locations

The Pharmacokinetics of Extended Duration High-dose Cefixime for the Decreased Susceptibility of Neisseria Gonorrhoeae: A Phase I Pilot Study

Phase 1

Completed

Conditions: Gonorrhoea

Interventions: Drug: Cefixime

First Posted Date: 2013-09-24

Last Posted Date: 2019-01-17

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 25

Registration Number: NCT01949363

Locations: 🇺🇸
Johns Hopkins Bayview Medical Center - Infectious Diseases, Baltimore, Maryland, United States

T and B Cell Responses in Autoimmune Diseases

Terminated

Conditions: Psoriasis
Arthritis, Rheumatoid
Crohn's Disease
Type 1 Diabetes Mellitus
Multiple Sclerosis

First Posted Date: 2013-09-20

Last Posted Date: 2016-10-26

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 68

Registration Number: NCT01947036

Locations: 🇺🇸
Yale University, New Haven, Connecticut, United States
🇺🇸
Baylor Institute of Immunology Research - Clinical Rheumatology, Dallas, Texas, United States
🇺🇸
Emory University, Atlanta, Georgia, United States

and more 3 locations

Randomized MMF Withdrawal in Systemic Lupus Erythematosus (SLE)

Phase 2

Terminated

Conditions: Systemic Lupus Erythematosus
SLE

Interventions: Drug: Mycophenolate Mofetil
Drug: Hydroxychloroquine or Chloroquine
Drug: Prednisone

First Posted Date: 2013-09-20

Last Posted Date: 2020-08-17

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 102

Registration Number: NCT01946880

Locations: 🇺🇸
UCSD, San Diego, California, United States
🇺🇸
UCSF School of Medicine, San Francisco, California, United States
🇺🇸
University of Miami Hospitals and Clinics, Miami, Florida, United States

and more 16 locations

H7N9 Mix and Match With AS03 and MF59 in Healthy Adults

Phase 2

Completed

Conditions: Influenza

Interventions: Drug: AS03
Biological: Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013
Drug: MF59

First Posted Date: 2013-09-13

Last Posted Date: 2017-07-06

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 980

Registration Number: NCT01942265

Locations: 🇺🇸
Saint Louis University - Center for Vaccine Development, Saint Louis, Missouri, United States
🇺🇸
University of Maryland School of Medicine - Center for Vaccine Development - Baltimore, Baltimore, Maryland, United States
🇺🇸
Vanderbilt University Medical Center - Infectious Diseases, Nashville, Tennessee, United States

and more 2 locations

H7N9 Mix and Match With MF59 in Healthy Adults

Phase 2

Completed

Conditions: Influenza

Interventions: Biological: Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013
Drug: MF59

First Posted Date: 2013-09-10

Last Posted Date: 2016-12-12

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 700

Registration Number: NCT01938742

Locations: 🇺🇸
Emory Vaccine Center - The Hope Clinic, Decatur, Georgia, United States
🇺🇸
Cincinnati Children's Hospital Medical Center - Infectious Diseases, Cincinnati, Ohio, United States
🇺🇸
University of Texas Medical Branch - Pediatrics - Infectious Diseases and Immunology - Galveston, Galveston, Texas, United States

and more 1 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy